News

Back

Bone Therapeutics and Catalent sign agreements to streamline production of the allogeneic cell therapy product, ALLOB

October 29th 2020

BioPark

Catalent to acquire Bone Therapeutics’ cell therapy manufacturing facility for EUR 12 million.
Bone Therapeutics and Catalent shall enter into a supply agreement for the further development of ALLOB.
Please discorver the press release here.